Search | Clinical Trials Finder

Conditions: Breast Cancer
Interventions: high performance liquid chromatography, laboratory biomarker analysis, spectroscopy; Other · Procedure
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: Up to 120 Years · Female only
Enrollment: 1,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Lymphoma, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myeloproliferative Neoplasms, Myelofibrosis, Myelodysplasia, Refractory Anemia, High Risk Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Diffuse Large Cell Non Hodgkins Lymphoma, Lymphoblastic Lymphoma, Burkitt Lymphoma, High Grade Non-Hodgkin's Lymphoma, Adult, Multiple Myeloma, Juvenile Myelomonocytic Leukemia, Biphenotypic/Undifferentiated/Prolymphocytic Leukemias, MRD Positive Leukemia, Natural Killer Cell Malignancies, Acquired Bone Marrow Failure Syndromes
Interventions: HSCT with TBI Regimen, HSCT with Non-TBI Regimen; Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 60 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: CIN 2/3, HPV Infection, Pre-Cancerous Dysplasia, Cervical Dysplasia, HPV Related Disease
Interventions: Artesunate vaginal insert, Placebo vaginal insert; Drug
Lead sponsor: Frantz Viral Therapeutics, LLC; Industry
Eligibility: 25 Years to 100 Years · Female only
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 7
States / cities: Fort Myers, Florida • Ann Arbor, Michigan • Cleveland, Ohio + 2 more

Conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions: aldesleukin; Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: Up to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Carcinoma, Non Small Cell Lung
Interventions: Lifestyle counseling; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 21 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Refractory and/or Relapsed Metastatic Solid Tumors
Interventions: Cyclophosphamide, Fludarabine, low dose total body irradiation, Melphalan, Tacrolimus; Drug · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 1 Year to 50 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2030
U.S. locations: 3
States / cities: Baltimore, Maryland • The Bronx, New York • Valhalla, New York

Conditions: Pregnancy Related, Pregnancy Complications, Pregnancy, High Risk
Interventions: Relugolix + Estradiol + Norethindrone Acetate; Drug
Lead sponsor: Sumitomo Pharma Switzerland GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Marlborough, Massachusetts

Conditions: Lymphoma, Leukemia, Myelodysplastic Syndrome
Interventions: Fludarabine, Busulfan, Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 6 Months to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia in Remission, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Mixed Phenotype Acute Leukemia, Hematopoietic and Lymphoid Cell Neoplasm
Interventions: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Cyclophosphamide, Total-Body Irradiation, Peripheral Blood Stem Cell Transplantation, Bone Marrow Transplantation, Mycophenolate Mofetil, Recombinant Granulocyte Colony-Stimulating Factor, Fludarabine Phosphate, Tacrolimus, Bone Marrow Aspiration and Biopsy, Biospecimen Collection; Biological · Drug · Radiation + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Sarcoma, Kaposi, Lymphoma, Non-Hodgkin, HIV Infections, Lymphoma, AIDS-Related
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 23
States / cities: Menlo Park, California • San Francisco, California • San Rafael, California + 15 more

Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission, Blasts Under 10 Percent of Bone Marrow Nucleated Cells, Therapy-Related Myeloid Neoplasm
Interventions: Laboratory Biomarker Analysis, Nivolumab; Other · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HSIL, High Grade Squamous Intraepithelial Lesion, HPV-Related Squamous Cell Carcinoma, Anal HSIL
Interventions: EXE-346 Probiotic, Placebo, Usual Care High Resolution Anoscopy (HRA); Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HPV-Related Oropharynx Squamous Cell Carcinoma
Interventions: Radiation therapy, Cisplatin, Surgery; Radiation · Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 3
States / cities: St Louis, Missouri • Fargo, North Dakota • Sioux Falls, South Dakota

Conditions: Malignant Neoplasm, Musculoskeletal Complications
Interventions: zoledronic acid, pharmacological study; Drug · Other
Lead sponsor: University of Southern California; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 2
States / cities: Los Angeles, California • San Diego, California

Conditions: AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage I Grade 3 Follicular Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma, HIV Infection, Plasmablastic Lymphoma, Primary Effusion Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma
Interventions: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Laboratory Biomarker Analysis, Pharmacological Study, Prednisone, Rituximab, Vincristine Sulfate, Vorinostat; Drug · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2022
U.S. locations: 35
States / cities: Montgomery, Alabama • La Jolla, California • Los Angeles, California + 16 more

Conditions: EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
Interventions: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs); Biological
Lead sponsor: Atara Biotherapeutics; Industry
Eligibility: Not listed
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Hematologic Malignancy, Myelodysplastic Syndrome (MDS), Aplastic Anemia
Interventions: haplo/cord transplant; Biological
Lead sponsor: Joanne Kurtzberg, MD; Other
Eligibility: Up to 55 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Breast Carcinoma
Interventions: Laboratory Biomarker Analysis; Other
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years to 80 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Untreated Adult Acute Myeloid Leukemia
Interventions: Laboratory Biomarker Analysis, Liposomal Cytarabine-Daunorubicin CPX-351; Other · Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Palo Alto, California • Seattle, Washington

Conditions: Lung Cancer, Precancerous Condition, Tobacco Use Disorder
Interventions: calcitriol, laboratory biomarker analysis, pharmacological study; Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 40 Years to 79 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Ringed Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes
Interventions: iodine I 131 monoclonal antibody BC8, fludarabine phosphate, total-body irradiation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, cyclosporine, mycophenolate mofetil, laboratory biomarker analysis; Radiation · Drug · Procedure + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 16 Years to 50 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2019
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Oncology
Interventions: Survey; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: Not listed
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cancer
Interventions: Cardiac Aggressive Risk MitigAtion Plan; Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cardiotoxicity, Lung Cancer Stage III, Lung Cancer Stage II, Radiation Toxicity
Interventions: Chemoradiation; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 8
States / cities: Birmingham, Alabama • Boston, Massachusetts • St Louis, Missouri + 5 more

Search by objective public record fields.

Nutrition-Related Biomarkers in Predicting Breast Cancer Risk in Women

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)

Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Healthy Directions After Lung Surgery Pilot

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy

Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

A Study of Patients With AIDS Syndrome

Nivolumab in AML in Remission at High Risk for Relapse

CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial

The Minimalist Trial-2

Genetics in Predicting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid

Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas

Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies

Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers

Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia

Calcitriol in Preventing Lung Cancer in Smokers and Former Smokers at High Risk of Lung Cancer

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Using Surveys to Examine the Association of Exposure to ML Mortality Risk Predictions With Medical Oncologists' Prognostic Accuracy and Decision-making

Cardiac Aggressive Risk Mitigation in Thoracic Radiotherapy (CARMA) Trial

Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy